Core Viewpoint - The company Infinitus (300582.SZ) has approved a capital increase and equity transfer agreement involving its wholly-owned subsidiary, aiming to invest in Qinghai Chunwarm Biotechnology Co., Ltd. and its existing shareholders [1][2] Group 1: Investment Details - Infinitus plans to invest a total of 13.44 million yuan in cash, which includes a capital increase of 1.344 million yuan and the remainder as capital premium [1] - The company will acquire all registered capital of 1.56 million yuan from Blincao Biotechnology Co., Ltd. for 1.56 million yuan [1] - After the transaction, Infinitus will hold 2.62% direct equity in the target company and an additional 3.04% indirectly through Blincao Biotechnology [1] Group 2: Profit Guarantees - The controlling shareholder and chairman, Guichaohua, has committed to a buyback agreement if the target company's net profit is negative for the years 2026 and 2027, or if the cumulative net profit for 2026, 2027, and 2028 does not reach 60 million yuan [2] - This transaction is classified as a related party transaction due to the buyback commitment [2]
英飞特(300582.SZ):拟对外投资及上市公司实控人对本次投资承担或有回购义务